Inhibition of BACE1 for therapeutic use in Alzheimer's disease. - Wikidata - wikimedia - TriplyDB

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

http://www.wikidata.org/entity/Q34007475

about

Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs Amyloid precursor protein and amyloid precursor-like protein 2 in cancer β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease The normal and pathologic roles of the Alzheimer's β-secretase, BACE1 Silencing PP2A inhibitor by lenti-shRNA interference ameliorates neuropathologies and memory deficits in tg2576 mice.L655,240, acting as a competitive BACE1 inhibitor, efficiently decreases β-amyloid peptide production in HEK293-APPswe cells.Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine.Interaction between amyloid precursor protein and Nogo receptors regulates amyloid deposition.Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression.Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease.OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE.BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer's disease BACE1 elevation is associated with aberrant limbic axonal sprouting in epileptic CD1 mice.Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease.Increased expression of reticulon 3 in neurons leads to reduced axonal transport of β site amyloid precursor protein-cleaving enzyme 1.The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease.Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity.Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer's disease.Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics.The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials.

P2860

Q26740189-ADD75E3A-0567-43B7-9018-1B5665BC1CF1 Q26769909-DA2C19A6-9943-4B29-B84D-B15C643B30E7 Q28245473-EB76AE7A-C2F7-42BF-9BC8-6312E8E8D4B5 Q28610071-1211210D-68B2-414C-8CEA-ACF4E88A5D1C Q30559506-ABEA87F7-56AD-4A01-9EAB-897F6FE9BAEC Q34355809-AE7236E1-8E38-4718-926F-12E7D562D661 Q34636863-E764598D-8055-4F92-B459-3E18C0E7C540 Q35169514-F82C7B0E-C326-40DC-8600-958ED6C4F17D Q35551497-8FAEC655-2C24-45C8-8662-3966C3A785F3 Q35617556-5AB603E4-A7E5-4D99-A365-8A4FD7A70806 Q36221014-82C68334-5F62-4354-BDBD-A1811796B431 Q36427048-0BCB3621-808D-4AA5-AD0A-0C07521FD31D Q36447042-5BD6AAD5-D96D-4BF6-BB27-77E0070FCDF2 Q37065293-C99A2D3A-8353-40AA-9619-7C81AC7F70BE Q37234006-2B604D9F-865F-4C02-AA4D-6D8A8D17FCC9 Q37884646-D6476654-2E3B-4B4A-AFAC-6E43FC5225A6 Q38026045-51F938CB-3C04-415D-A445-F14FD7B7B94B Q39108867-2C781148-84E0-42D5-9A84-C7117A262001 Q40350445-0D961F34-DF0B-4C51-92CF-E14B524AA943 Q47555674-48094803-9574-4392-AC5F-D1386E1CFA3D Q51760979-441194A3-2F23-404F-8641-471FD72F4039

P2860

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

http://www.wikidata.org/entity/Q34007475

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

@ast

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

@en

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

@nl

type

label

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

@ast

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

@en

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

@nl

prefLabel

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

@ast

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

@en

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

@nl

P1433

Q34007475-46939A1F-071C-42DA-80DB-09399730E118

P1476

Q34007475-17A6C700-B96E-47E7-A790-F19774272096

P2093

Q34007475-7B5034F7-8C25-416A-839A-D618F30D988E

Q34007475-C8C3B0C0-0848-4A8B-B87D-DD348F92FFE7

P2860

Q34007475-03A956AE-354E-4E9E-8015-75CF04CBE8A1

Q34007475-0CBDDF62-277D-4305-9F75-EC2E38A7C9FD

Q34007475-0E3AEC17-944D-4228-B44C-BDB56CFED116

Q34007475-0F83945C-E1AF-40FE-92A7-6AA2A08BA733

Q34007475-0F915492-44FA-4D49-BDC0-9934B4CC3B68

Q34007475-10CAC2C1-5AB9-4848-A2A7-5332FACE300F

Q34007475-1306C718-9EBC-430E-8EC1-E4C3C7513A01

Q34007475-18C664C3-428A-4904-9BCD-AC1EEEE7825A

Q34007475-1CC5032A-46C3-4A51-98EE-D6B6D6B0A2E0

Q34007475-1E631D4E-B212-4CDD-8F61-128FEB27F9D7

P304

Q34007475-88FC6C6C-6EA6-41CF-90B9-80214A3A1E58

P31

Q34007475-4DE8C0C4-DA80-4BAA-B0D5-199DB221420C

P433

Q34007475-9D44565C-E2B4-4CF4-8571-B641C62D51EB

P478

Q34007475-E70EBEAD-A522-4BD0-AFCC-31128C0E98A4

P577

Q34007475-87175DF7-39EA-4E45-9437-1F27EE7CDF55

P698

Q34007475-EFEB3B57-4428-4FA4-846D-E6B4F9D98F50

P932

Q34007475-04D724C0-AE2D-4BE7-B70C-BFEA3CB919AB

P1433

International Journal of Clinical and Experimental Pathology

P1476

Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

@en

P2093

Riqiang Yan

http://www.w3.org/2001/XMLSchema#string

Xiaoyang Luo

http://www.w3.org/2001/XMLSchema#string

P2860

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity

Purification and cloning of amyloid precursor protein beta-secretase from human brain

BACE2 functions as an alternative alpha-secretase in cells

The transmembrane domain of the Alzheimer's beta-secretase (BACE1) determines its late Golgi localization and access to beta -amyloid precursor protein (APP) substrate

Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein

BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein

Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor

Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3

Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase

P304

618-628

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20661410

http://www.w3.org/2001/XMLSchema#string

P932

2907124

http://www.w3.org/2001/XMLSchema#string